99. 慢性特発性偽性腸閉塞症 Chronic intestinal pseudo-obstruction Clinical trials / Disease details

臨床試験数 : 4 / 薬物数 : 9 - (DrugBank : 2) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 4

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-000854-24-IT (EUCTR)	17/09/2021	18/10/2021	Phase II multicenter clinical trial, with treatment randomly assigned, in which patient nor physician are aware of the assigned treatment, active or placebo, to evaluate efficacy and safety of Velusetrag 15 mg (3 x 5 mg capsule) in patients with Chronic Intestinal Pseudo-Obstruction (CIPO)	Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial. - N/A	Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture similar to that of mechanical intestinal obstruction, although in the absence of any lesion occluding the gut. CIPO can be idiopathic or secondary. MedDRA version: 20.0;Level: SOC;Classification code 10017947;Term: Gastrointestinal disorders;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Velusetrag Product Code: [TD-5108 hydrochloride] INN or Proposed INN: Velusetrag Other descriptive name: THRX-199687 hydrochloride	ALFASIGMA S.P.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	16	Phase 2	Spain;Belgium;Italy
2	JPRN-jRCT2031190137	25/12/2019	20/11/2019	Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial	Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial	Chronic Intestinal Pseudo-obstruction CIPO, abdominal bloating	Two tablets of the investigational product per dosing (400 mg of rifaximin) or the placebo are orally administered 3 times daily for 4 weeks.	Ohkubo Hidenori	NULL	Not Recruiting	>= 20age old	< 75age old	Both	12	Phase 2	Japan
3	NCT04118699 (ClinicalTrials.gov)	December 25, 2019	23/9/2019	Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial	Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 Trial	Chronic Intestinal Pseudo-obstruction	Drug: Rifaximin oral tablet;Drug: Placebo oral tablet	Yokohama City University	ASKA Pharmaceutical Co., Ltd.	Active, not recruiting	20 Years	74 Years	All	12	Phase 2	Japan
4	NCT00793247 (ClinicalTrials.gov)	December 2008	18/11/2008	Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)	A Double-Blind, Placebo-Controlled, Cross-Over, Multiple (n=1) Trial to Evaluate the Effects of R093877 in Patients With Chronic Intestinal Pseudo-Obstruction (CIP).	Chronic Intestinal Pseudo-Obstruction	Drug: PRU-PLA-PRU-PLA;Drug: PLA-PRU-PLA-PRU;Drug: PLA-PRU-PRU-PLA;Drug: PRU-PLA-PLA-PRU	Movetis	NULL	Completed	18 Years	N/A	Both		Phase 2	United Kingdom